Profile data is unavailable for this security.
About the company
Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of technologies for antibody drug creation, among others. It also involved in the contracting, retail and wholesale, and insurance agency businesses. The Biochemical segment manufactures and sells medical and industrial materials, mainly amino and nucleic acids, and healthcare products. This segment also designs and constructs facilities.
- Revenue in JPY (TTM)346.03bn
- Net income in JPY60.85bn
- Incorporated1949
- Employees7.53k
- LocationKyowa Hakko Kirin Co LtdRoom 5485F, Otemachi Bldg., 1-6-1, Ote-machiCHIYODA-KU 100-0004JapanJPN
- Phone+81 352057200
- Fax+81 352057182
- Websitehttp://www.kyowa-kirin.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alfresa Holdings Corporation | 2.62tn | 39.44bn | 695.65bn | 11.90k | 16.18 | 1.39 | 13.98 | 0.2654 | 182.89 | 182.89 | 12,162.99 | 2,123.38 | 2.00 | 17.68 | 4.34 | 220,216,900.00 | 3.02 | 2.44 | 8.33 | 7.52 | 7.64 | 7.19 | 1.51 | 1.19 | 1.03 | -- | 0.0042 | 22.08 | 2.00 | 1.74 | 15.20 | 11.37 | 12.74 | 10.90 |
| Santen Pharmaceutical Co Ltd | 228.51bn | 34.37bn | 707.14bn | 3.81k | 20.62 | 2.33 | 15.57 | 3.09 | 84.22 | 84.22 | 559.95 | 744.09 | 0.5903 | 2.98 | 3.03 | 60,055,450.00 | 8.88 | 9.94 | 10.37 | 12.02 | 60.97 | 62.49 | 15.05 | 16.62 | 3.00 | 349.79 | 0.0968 | 31.74 | 12.98 | 13.57 | 62.20 | 16.37 | 22.46 | 5.39 |
| Kyowa Hakko Kirin Co Ltd | 346.03bn | 60.85bn | 1.29tn | 7.53k | 20.13 | 1.89 | 15.62 | 3.73 | 111.05 | 111.05 | 631.50 | 1,180.49 | 0.4837 | 1.59 | 3.63 | 45,941,850.00 | 8.51 | 4.22 | 9.46 | 4.80 | 65.10 | 62.25 | 17.59 | 8.58 | 3.95 | 36.75 | 0.008 | 46.62 | 1.56 | 1.19 | 40.88 | 12.13 | -3.67 | 6.19 |
| ONO PHARMACEUTICAL CO., LTD. | 284.79bn | 57.92bn | 1.40tn | 3.48k | 22.88 | 2.35 | 20.63 | 4.92 | 112.63 | 112.63 | 553.77 | 1,098.51 | 0.4681 | 2.52 | 3.67 | 81,835,340.00 | 9.53 | 6.10 | 10.71 | 6.78 | 73.13 | 74.59 | 20.36 | 17.48 | 2.88 | -- | 0.0015 | 61.80 | 6.96 | 12.89 | -9.87 | 17.02 | 31.44 | 2.13 |
| Sumitomo Dainippon Pharma Co Ltd | 461.64bn | 35.98bn | 1.48tn | 6.27k | 41.02 | 3.01 | 28.71 | 3.20 | 90.57 | 90.57 | 1,161.95 | 1,236.10 | 0.5545 | 1.64 | 3.88 | 73,650,610.00 | 4.32 | 4.07 | 5.82 | 5.37 | 75.97 | 74.64 | 7.79 | 7.12 | 1.47 | -- | 0.0619 | 27.95 | 14.32 | 6.07 | 70.67 | 39.71 | 4.27 | 0.00 |
Data as of Dec 19 2018. Currency figures normalised to Kyowa Hakko Kirin Co Ltd's reporting currency: Japanese Yen JPY
10.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 10 Oct 2018 | 17.82m | 3.09% |
| Nikko Asset Management Co., Ltd.as of 07 Dec 2018 | 7.52m | 1.31% |
| Daiwa Asset Management Co. Ltd.as of 30 Nov 2018 | 7.11m | 1.23% |
| The Vanguard Group, Inc.as of 31 Oct 2018 | 6.43m | 1.12% |
| Wellington Management Co. LLPas of 30 Nov 2018 | 6.30m | 1.09% |
| BlackRock Fund Advisorsas of 06 Dec 2018 | 4.34m | 0.75% |
| Norges Bank Investment Managementas of 31 Dec 2017 | 4.21m | 0.73% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 31 Oct 2018 | 3.68m | 0.64% |
| OppenheimerFunds, Inc.as of 31 Aug 2018 | 1.82m | 0.32% |
| Asset Management One Co., Ltd.as of 18 Sep 2018 | 1.42m | 0.25% |
More ▼
Data from 31 Dec 2017 - 30 Sep 2018Source: FactSet Research Systems Inc.
